Read-across
is an in silico method applied in chemical risk assessment
for data-poor chemicals. The read-across outcomes for repeated-dose
toxicity end points include the no-observed-adverse-effect level (NOAEL)
and estimated uncertainty for a particular category of effects. We
have previously developed a new paradigm for estimating NOAELs based
on chemoinformatics analysis and experimental study qualities from
selected analogues, not relying on quantitative structure–activity
relationships (QSARs) or rule-based SAR systems, which are not well-suited
to end points for which the underpinning data are weakly grounded
in specific chemical–biological interactions. The central hypothesis
of this approach is that similar compounds have similar toxicity profiles
and, hence, similar NOAEL values. Analogue quality (AQ) quantifies
the suitability of an analogue candidate for reading across to the
target by considering similarity from structure, physicochemical,
ADME (absorption, distribution, metabolism, excretion), and biological
perspectives. Biological similarity is based on experimental data;
assay vectors derived from aggregations of ToxCast/Tox21 data are
used to derive machine learning (ML) hybrid rules that serve as biological
fingerprints to capture target–analogue similarity relevant
to specific effects of interest, for example, hormone receptors (ER/AR/THR).
Once one or more analogues have been qualified for read-across, a
decision theory approach is used to estimate confidence bounds for
the NOAEL of the target. The confidence interval is dramatically narrowed
when analogues are constrained to biologically related profiles. Although
this read-across process works well for a single target with several
analogues, it can become unmanageable when, for example, screening
multiple targets (e.g., virtual screening library) or handling a parent
compound having numerous metabolites. To this end, we have established
a digitalized framework to enable the assessment of a large number
of substances, while still allowing for human decisions for filtering
and prioritization. This workflow was developed and validated through
a use case of a large set of bisphenols and their metabolites.